View Older Stories
-
Cogent (COGT) PT Raised to $55 at H.C. Wainwright
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
-
Cogent Biosciences submits drug application for GIST treatment
-
Jefferies says these are the best SMID-cap biotech stocks to buy
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
FDA accepts Cogent's drug application for rare blood disorder treatment
-
Cogent (COGT) PT Raised to $52; Piper Sandler 'Remain Buyers Ahead of 2H26 Bezuclastinib Launch'
-
Cogent Biosciences gets FDA breakthrough therapy status for GIST drug combo
-
FDA agrees to review Cogent's bezuclastinib application for rare cancer
-
H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
Cogent Biosciences outlines 2026 milestones for bezuclastinib drug applications
-
Cogent Biosciences (COGT) call put ratio 3.4 calls to 1 put as share price up 2.1%
-
UBS Starts Cogent (COGT) at Buy
-
Cogent (COGT) PT Raised to $52 at H.C. Wainwright
-
Raymond James on Cogent (COGT): 'We anticipate shares will continue to work in 2026'
-
Cogent Biosciences submits drug application for systemic mastocytosis
-
Cogent (COGT) PT Lowered to $49 at Leerink Partners
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
Cogent's (COGT) Bezuclastinib Up For Approval in 2026 - Stifel
-
Cogent Biosciences reports positive APEX trial results for bezuclastinib
-
Cogent Biosciences presents full SUMMIT trial results for bezuclastinib
-
Increasing unusual call option volume: IRBT BOX CAR WRAP PSTG AEVA GENI HTGC COGT
-
Increasing unusual call option volume: BRR COGT JANX MDB EH KMB TSEM UNFI SIG FRPT TXG
-
Cogent (COGT) PT Raised to $60 at Raymond James, 'remains our Analyst Current Favorite'
-
Cogent (COGT) PT Raised to $50 at Leerink Partners
-
Stifel Upgrades Cogent (COGT) to Buy
-
Wedbush Upgrades Cogent (COGT) to Outperform
-
Stifel Reiterates Hold Rating on Cogent (COGT)
-
Cogent Biosciences (COGT) files mixed shelf
-
Cogent Biosciences presents KRAS inhibitor data at cancer conference
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
Stifel Starts Cogent (COGT) at Hold
-
This biotech stock is a Top Pick at Raymond James
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT), 'Remains a Top Pick After CEO Fireside Chat'
-
Raymond James Adjust Analyst Current Favorites List
-
Cogent (COGT) PT Raised to $20 at Guggenheim
-
Cogent Biosciences (COGT) spreader of November 13 and 20 calls
-
Increasing unusual call option volume: COGT OMI AIP TDW AMCR ULCC DOCN PTIR
-
Cogent (COGT) PT Raised to $22 at Citi, Removes 30d Upside Catalyst Watch
-
Cogent Biosciences completes upsized $230 million public offering
-
Cogent Biosciences prices $200 million stock offering at $9 per share
-
Cogent Biosciences announces $150 million public stock offering
-
After-hours movers: Mobileye, RxSight, Cogent Biosciences
-
Cogent (COGT) PT Raised to $28 at Jefferies
-
Cogent (COGT) PT Raised to $18 at Leerink Partners
-
Cogent Biosciences (COGT) reports positive results from mastocytosis drug trial
-
Citi Opens 30d Upside Catalyst Watch on Cogent (COGT)

